Global Amyotrophic Lateral Sclerosis (ALS) Market - 2023-2030

Market Overview

The Global Amyotrophic Lateral Sclerosis Market size reached US$ 0.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.0 billion by 2030. The global amyotrophic lateral sclerosis market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The ongoing research efforts and the growing clinical trials for novel drugs are driving up demand for amyotrophic lateral sclerosis market trends.

The ALS market encompasses a range of therapies, including FDA-approved medications such as Edaravone (Radicava) and riluzole, which have demonstrated efficacy in slowing the decline in functional abilities. Additionally, supportive care interventions, assistive devices, and multidisciplinary care play a crucial role in managing symptoms and optimizing patient outcomes.

The global amyotrophic lateral sclerosis market is driven by the factors such as the rising prevalence of amyotrophic lateral sclerosis, increasing awareness, advances in research and development activities, and technological advancements in treatment options.

Market Dynamics

Advancements in Research and Developments Drive the Growth of the Amyotrophic Lateral Sclerosis Market

Advancements in research and developments play a pivotal role in driving the growth of the amyotrophic lateral sclerosis (ALS) market. Research efforts aimed at understanding the underlying mechanisms of ALS, identifying potential therapeutic targets, and developing innovative treatment approaches have the potential to transform the landscape of ALS care.

Ongoing research and development efforts are exploring various therapeutic approaches for ALS. This includes the development of small molecule drugs, gene therapies, stem cell-based therapies, and other innovative treatment modalities. The discovery and development of new drugs and treatment strategies provide hope for patients and drive market growth by expanding the available treatment options.

For instance, on September 29, 2022, the Food and Drug Administration (FDA) approved Trusted Source a new oral drug to treat amyotrophic lateral sclerosis or ALS, a nervous system disease that weakens muscles.

Rising Awareness Also Drives the Growth of the Amyotrophic Lateral Sclerosis Market

Increasing awareness about ALS symptoms, risk factors, and the importance of seeking medical attention can lead to earlier diagnosis. Early diagnosis allows for timely intervention and the initiation of appropriate treatments, which helps to manage symptoms and improve patient outcomes. Increased awareness campaigns and educational initiatives raise public consciousness about ALS, leading to more proactive healthcare-seeking behaviors and improved access to care.

Public awareness of ALS generates interest and support for research initiatives. As public understanding of the disease and its impact grows, individuals, philanthropic organizations, and government agencies allocate more resources toward funding ALS research. Increased funding accelerates scientific advancements, enhance collaboration, and attract talent to the field, ultimately driving the development of new therapies and treatment approaches.

High Cost of the Treatment will Hamper the Growth of the Market

The available FDA-approved medications for ALS, such as Edaravone (Radicava) and riluzole, can be costly. These medications are often required for long-term use, adding to the financial burden on patients and healthcare systems. The high cost of medications limits accessibility and affordability, potentially hindering patient adherence to treatment regimens and impeding market growth.

The high cost of ALS treatment places a financial burden on healthcare systems and insurers. The expenses associated with medication coverage, hospitalizations, specialized care, and support services strain healthcare budgets. This can lead to reimbursement challenges, restrictive insurance coverage, and limited access to treatments, thereby impeding market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the amyotrophic lateral sclerosis market. The pandemic has led to disruptions in healthcare systems worldwide, with a shift in focus towards managing and treating COVID-19 patients. Non-essential healthcare services, including routine check-ups and follow-up visits for ALS patients, are delayed or canceled, impacting access to care and potentially affecting disease management.

Many ongoing clinical trials and research studies related to ALS are temporarily halted or faced delays due to the pandemic. This interruption in research activities has the potential to slow down the development of new therapies and treatment approaches for ALS.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global amyotrophic lateral sclerosis market. ALS research often involves collaborations and partnerships among researchers, institutions, and pharmaceutical companies across different countries. The conflict disrupts or strains these collaborations, potentially impacting the progress and pace of ALS research and the development of innovative treatments.

Segment Analysis

The global amyotrophic lateral sclerosis market is segmented based on drug type, treatment type, end-user, and region.

Edaravone (Radicava) from the Drug Type Segment Accounts for 36.7% of the Amyotrophic Lateral Sclerosis Market Share

Edaravone (Radicava) is indeed an important medication in the treatment of amyotrophic lateral sclerosis (ALS) and has shown significant market dominance. Edaravone is an intravenous medication approved by the FDA for the treatment of ALS. It acts as a free radical scavenger and aims to reduce oxidative stress, which is believed to contribute to the progression of ALS.

Edaravone has demonstrated efficacy in clinical trials by slowing down the decline in functional abilities in ALS patients. It has become an essential part of the treatment regimen for ALS, particularly in countries where it is approved and available. Due to its effectiveness and widespread use, Edaravone has garnered a significant market share in the ALS pharmaceutical segment. Its dominance can be attributed to the limited treatment options available for ALS and the need for disease-modifying therapies.

For instance, on May 12, 2023, the US Food and Drug Administration (FDA) granted approval to oral edaravone (RADICAVA ORS) for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA ORS is the sixth disease-modifying drug approved to treat ALS. RADICAVA ORS will be made available in the United States (US).

Geographical Analysis

North America Accounted for Approximately 40.4% of the Market Share Owing to the Advanced Healthcare Infrastructure and Technological Advancements

North America, particularly the United States and Canada, possesses a highly developed healthcare infrastructure with advanced medical facilities, including specialized ALS clinics, research centers, and hospitals. These facilities provide comprehensive care for ALS patients, including diagnostic services, specialized treatments, and supportive care.

North America has a strong research and development ecosystem, with renowned academic institutions, biopharmaceutical companies, and government support for ALS research. The region's scientific expertise, collaborations, and funding opportunities have facilitated the discovery of novel therapeutic targets, clinical trial advancements, and the development of potential treatments.

Competitive Landscape

The major global players in the amyotrophic lateral sclerosis market include: Sanofi S.A., Brainstorm Cell Therapeutics, Biogen Inc., Bausch Health, F Hoffmann-la Roche Ltd, Ionis Pharmaceuticals, Mylan Pharma, Sun Pharma, Orion Pharmaceuticals, and AB Science among others.

Why Purchase the Report?

• To visualize the global amyotrophic lateral sclerosis market segmentation based on drug type, treatment type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of amyotrophic lateral sclerosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global amyotrophic lateral sclerosis market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies